Ossiam purchased a new position in shares of Amgen, Inc. (NASDAQ:AMGN) during the 2nd quarter, HoldingsChannel reports. The firm purchased 483 shares of the medical research company’s stock, valued at approximately $89,000.
Several other institutional investors and hedge funds have also made changes to their positions in AMGN. Advisors Preferred LLC acquired a new position in Amgen in the 2nd quarter valued at $30,000. Arbor Wealth Management LLC grew its stake in Amgen by 154.5% in the 2nd quarter. Arbor Wealth Management LLC now owns 168 shares of the medical research company’s stock valued at $31,000 after buying an additional 102 shares during the last quarter. C J Advisory Inc acquired a new position in Amgen in the 1st quarter valued at $40,000. Ashburton Jersey Ltd acquired a new position in Amgen in the 2nd quarter valued at $42,000. Finally, Sound Income Strategies LLC grew its stake in Amgen by 402.1% in the 2nd quarter. Sound Income Strategies LLC now owns 236 shares of the medical research company’s stock valued at $43,000 after buying an additional 189 shares during the last quarter. Institutional investors own 76.28% of the company’s stock.
In related news, Director R Sanders Williams sold 425 shares of Amgen stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $183.04, for a total transaction of $77,792.00. Following the completion of the transaction, the director now directly owns 16,336 shares of the company’s stock, valued at approximately $2,990,141.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ronald D. Sugar sold 2,000 shares of Amgen stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $187.58, for a total transaction of $375,160.00. Following the transaction, the director now directly owns 16,336 shares of the company’s stock, valued at $3,064,306.88. The disclosure for this sale can be found here. Insiders have sold a total of 17,851 shares of company stock valued at $3,659,900 over the last three months. 0.25% of the stock is currently owned by insiders.
A number of research firms recently issued reports on AMGN. Credit Suisse Group reiterated an “outperform” rating and issued a $225.00 target price (up from $202.00) on shares of Amgen in a research note on Friday, August 16th. Morgan Stanley lowered their target price on shares of Amgen from $211.00 to $207.00 and set an “overweight” rating on the stock in a research note on Monday, July 15th. William Blair reiterated a “hold” rating on shares of Amgen in a research note on Friday, August 30th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $230.00 target price (up from $221.00) on shares of Amgen in a research note on Thursday, September 5th. Finally, Evercore ISI reiterated a “hold” rating on shares of Amgen in a research note on Sunday, August 11th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and ten have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $217.33.
Amgen stock traded up $1.85 during mid-day trading on Friday, reaching $195.86. The company had a trading volume of 677,996 shares, compared to its average volume of 2,890,083. The company has a quick ratio of 2.60, a current ratio of 2.89 and a debt-to-equity ratio of 2.58. Amgen, Inc. has a 52 week low of $166.30 and a 52 week high of $211.90. The company has a 50 day moving average of $196.19 and a 200-day moving average of $185.15. The firm has a market cap of $118.06 billion, a price-to-earnings ratio of 13.60, a PEG ratio of 2.30 and a beta of 1.11.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, July 30th. The medical research company reported $3.97 EPS for the quarter, topping analysts’ consensus estimates of $3.58 by $0.39. The company had revenue of $5.87 billion during the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a net margin of 33.78% and a return on equity of 76.17%. The firm’s revenue for the quarter was down 3.1% compared to the same quarter last year. During the same period last year, the firm earned $3.83 EPS. On average, analysts predict that Amgen, Inc. will post 14.3 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Friday, September 6th. Investors of record on Thursday, August 15th were issued a dividend of $1.45 per share. This represents a $5.80 annualized dividend and a yield of 2.96%. The ex-dividend date of this dividend was Wednesday, August 14th. Amgen’s dividend payout ratio is currently 40.28%.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.